Oruka Therapeutics, Inc.
Develops long-acting antibody therapies for chronic inflammatory and skin diseases.
ORKA | NDAQ
Overview
Corporate Details
- ISIN(s):
- US6876041087 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 855 OAK GROVE AVE., 94025 MENLO PARK
- Website:
- https://orukatx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologics for chronic dermatologic and inflammatory diseases. The company leverages advanced antibody engineering to create potentially best-in-class monoclonal antibodies aimed at redefining the standard of care for patients with plaque psoriasis and psoriatic arthritis. Oruka's mission is to deliver therapies that provide high rates of complete disease clearance with a significantly reduced dosing frequency, potentially as few as one or two doses per year. Its lead candidate, ORKA-001, an antibody targeting the IL-23 cytokine, is in clinical development for moderate-to-severe plaque psoriasis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Oruka Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oruka Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oruka Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
